Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
68,501,762
-
Share change
-
+4,467,026
-
Total reported value
-
$629,544,777
-
Put/Call ratio
-
0.44%
-
Price per share
-
$9.19
-
Number of holders
-
99
-
Value change
-
+$39,222,348
-
Number of buys
-
56
-
Number of sells
-
48
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q1 2023
As of 31 Mar 2023,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,501,762 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., BROWN CAPITAL MANAGEMENT LLC, BlackRock Inc., VANGUARD GROUP INC, HHLR ADVISORS, LTD., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MACQUARIE GROUP LTD, NEW YORK STATE COMMON RETIREMENT FUND, and PERCEPTIVE ADVISORS LLC.
This page lists
99
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.